Exact Mass: 416.2567
Exact Mass Matches: 416.2567
Found 500 metabolites which its exact mass value is equals to given mass value 416.2567
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Alfentanil
A short-acting opioid anesthetic and analgesic derivative of fentanyl. It produces an early peak analgesic effect and fast recovery of consciousness. Alfentanil is effective as an anesthetic during surgery, for supplementation of analgesia during surgical procedures, and as an analgesic for critically ill patients. [PubChem] D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D000777 - Anesthetics D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics N - Nervous system > N01 - Anesthetics > N01A - Anesthetics, general > N01AH - Opioid anesthetics D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist D002491 - Central Nervous System Agents > D000700 - Analgesics
Distigmine
ATC code: N07AA03
manoalide
A sesterterpenoid isolated from the marine sponge Luffariella variabilis and which has been shown to exhibit inhibitory activity towards phospholipase A2. D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D004791 - Enzyme Inhibitors > D010726 - Phosphodiesterase Inhibitors D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators D000893 - Anti-Inflammatory Agents D018501 - Antirheumatic Agents
Colupox b
Colupox b is found in alcoholic beverages. Colupox b is isolated from hops. Isolated from hops. Colupox b is found in alcoholic beverages.
Forasartan
Forasartan, a specific angiotensin II antagonist, is used alone or with other antihypertensive agents to treat hypertension. Forasartan competes with angiotensin II for binding at the AT1 receptor subtype. As angiotensin II is a vasoconstrictor which also stimulates the synthesis and release of aldosterone, blockage of its effects results in a decreases in systemic vascular resistance. C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C66930 - Angiotensin II Receptor Antagonist
N-Eicosapentaenoyl Asparagine
N-eicosapentaenoyl asparagine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is an Eicosapentaenoic acid amide of Asparagine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Eicosapentaenoyl Asparagine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Eicosapentaenoyl Asparagine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.
9-Octadecenoic acid (9Z)-, (2-hydroxy-2-oxido-1,2-oxaphospholan-4-yl)methyl ester
Efegatran
Elarofiban
3alpha-Angeloyloxy-18-hydroxy-ent-labd-8(17)-13dien-15,16-olide
(2E,6E,9E)-11-Hydroxy-7-(hydroxymethyl)-4,11-dimethyl-4-(4-methyl-3-penten-1-yl)-8-oxo-2,6,9-cycloundecatrien-1-yl 3-methyl-2-butenoate
Distigmine
N - Nervous system > N07 - Other nervous system drugs > N07A - Parasympathomimetics > N07AA - Anticholinesterases D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D002800 - Cholinesterase Inhibitors D004791 - Enzyme Inhibitors
(ent-15beta)-16alpha,17-Epoxide,15-angeloyl-15-Hydroxy-16-kauren-19-oic acid|Perymenic acid
7alpha-methoxy-8,11,13-abietatriene-18-succinic acid|abiesadine G
15-alpha-angeloyloxykauren-19-oic acid 16-epoxide|15-angeloyloxy-16,17-epoxy-19-kauronoic acid
(12E,20Z,18S)-7,8-dihydro-8-hydroxyvariabilin|(12E,20Z,18S)-8-Hydroxyvariabilin|6, 7-Dihydro, 7-hydroxy-Variabilin+
(4R,5S,7S,8S,10R,11R,2S)-7-angeloyloxy-8-(alpha-methylbutyryloxy)longipin-2-en-1-one
21,24,25,26,27-pentanor-15,22-oxo-7alpha,23-dihydroxy-apotirucalla(eupha)-1-en-3-one
3,6-Di-O-acetylasterone|3beta,6alpha-Diacetoxy-5alpha-pregn-9(11)-en-20-on|3beta,6alpha-diacetoxy-5alpha-pregn-9(11)-en-20-one|diacetyl asterone
15-Angeloyl-(ent-15beta)-9, 15-Dihydroxy-16-kauren-19-oic acid|15alpha-angeloyloxy-9beta-hydroxy-ent-kaurenic acid
ent-3beta-hydroxy-14beta-tigloyloxybeyer-15-en-19-oic acid
Di-Ac-(3beta,4beta,5alpha,17(20)Z)-en-16-one-3,4-Dihydroxypregn-17(20)-en-16-one
6alpha,8alpha-dihydroxy-23-oxo-13(14),15,17-trien-16,19-olide
(5S,6E,10R)-5-beta-D-glucopyranosyloxy-3,10-dihydroxy-3,7,11-trimethyldodeca-1,5,11-triene|amarantholidoside II
11,12-Dihydroxy-19-(3-methyl-2-butanoyloxy)-8,11,13-abietatrien-7-on
3beta(H)-7beta,9alpha-diangelyloxy-1-oxolongipinane
2alpha-(2-methylbutyryloxy)-15,16-epoxylabda-7,13(16),14-trien-18-oic acid|2alpha-<2-methylbutyryloxy>-15,16-epoxylabda-7,13(16),14-trien-18-oic acid
6alpha,15(S)-dihydroxy-23-oxo-labd-8(22),13(14),17-trien-16(S),19-olide
8alpha-23-dihydroxy-23,6alpha-epoxy-labd-13(14),15,17-trien-16,19-olide
(3beta,5beta,14beta,16beta,20Z)-16-acetoxy-14,15-epoxy-3-hydroxy-24-norcholan-20(22)-en-21-al
(3R,3aR,5R,5aR,9S,11S,13bR)-3-[(2E)-erythro-4,5-dihydroxyhex-2-en-2-yl]-5,9-dihydroxy-3a-methyl-1,2,3,3a,4,5,5a,8,9,10,11,13b-dodecahydro-12H-6,11-methanocyclodeca[e]inden-12-one|erythro-11alpha-hydroxyneocyclocitrinol
(ent-15beta)-2,3-Epoxy-2-methylbutanoyl-15-Hydroxy-16-kauren-19-oic acid|Epoxyangeloxygrandifloric acid
(3alpha,9alpha,10??)-9,10-Dihydroxy-5-longipinanone
abiesadine K|methyl 15-hydroxy-8,11,13-abietatriene-18-succinate
abiesadine H|methyl 7alpha-hydroxy-8,11,13-abietatriene-18-succinate
2alpha-isovaleryloxy-15,16-epoxylabda-7,13(16),14-trien-18-oic acid
15-methoxy-8,11,13-abietatriene-18-succinic acid|abiesadine J
6alpha,11-Dihydroxy-19-(3-methyl-2-butanoyloxy)-7,9(11),13-abietatrien-12-on
15-(3-Methyl-2-butenoyl)-(ent-15beta)-9, 15-Dihydroxy-16-kauren-19-oic acid|9beta-hydroxy-15alpha-senecioyloxy-ent-kaurenic acid|9beta-hydroxy-15alpha-senecioyloxy-ent-kaurenoic acid
(Z)-(1R,3R,4R,4aS,8R,8aR)-3,4,8,8a-Tetramethyl-7-oxo-4-(2-(5-oxo-2,5-dihydrofuran-3-yl)ethyl)decahydronaphthalen-1-yl 2-methylbut-2-enoate
ALFENTANIL
D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D000777 - Anesthetics D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics N - Nervous system > N01 - Anesthetics > N01A - Anesthetics, general > N01AH - Opioid anesthetics D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist D002491 - Central Nervous System Agents > D000700 - Analgesics
C25H36O5_2-Butenoic acid, 2-methyl-, (4R,6R)-3,3,7,9-tetramethyl-6-(3-methyl-1-oxobutoxy)-11-oxotricyclo[5.4.0.0~2,8~]undec-9-en-4-yl ester, (2Z)
Ala Ile Ile Thr
Ala Ile Leu Thr
Ala Ile Thr Ile
Ala Ile Thr Leu
Ala Leu Ile Thr
Ala Leu Leu Thr
Ala Leu Thr Ile
Ala Leu Thr Leu
Ala Thr Ile Ile
Ala Thr Ile Leu
Ala Thr Leu Ile
Ala Thr Leu Leu
Gly Gly Lys Arg
Gly Gly Arg Lys
Gly Lys Gly Arg
Gly Lys Arg Gly
Gly Arg Gly Lys
Gly Arg Lys Gly
Ile Ala Ile Thr
Ile Ala Leu Thr
Ile Ala Thr Ile
Ile Ala Thr Leu
Ile Ile Ala Thr
Ile Ile Thr Ala
Ile Leu Ala Thr
Ile Leu Thr Ala
Ile Ser Val Val
Ile Thr Ala Ile
Ile Thr Ala Leu
Ile Thr Ile Ala
Ile Thr Leu Ala
Ile Val Ser Val
Ile Val Val Ser
Lys Gly Gly Arg
Lys Gly Arg Gly
Lys Arg Gly Gly
Leu Ala Ile Thr
Leu Ala Leu Thr
Leu Ala Thr Ile
Leu Ala Thr Leu
Leu Ile Ala Thr
Leu Ile Thr Ala
Leu Leu Ala Thr
Leu Leu Thr Ala
Leu Ser Val Val
Leu Thr Ala Ile
Leu Thr Ala Leu
Leu Thr Ile Ala
Leu Thr Leu Ala
Leu Val Ser Val
Leu Val Val Ser
Arg Gly Gly Lys
Arg Gly Lys Gly
Arg Lys Gly Gly
Ser Ile Val Val
Ser Leu Val Val
Ser Val Ile Val
Ser Val Leu Val
Ser Val Val Ile
Ser Val Val Leu
Thr Ala Ile Ile
Thr Ala Ile Leu
Thr Ala Leu Ile
Thr Ala Leu Leu
Thr Ile Ala Ile
Thr Ile Ala Leu
Thr Ile Ile Ala
Thr Ile Leu Ala
Thr Leu Ala Ile
Thr Leu Ala Leu
Thr Leu Ile Ala
Thr Leu Leu Ala
Thr Val Val Val
Val Ile Ser Val
Val Ile Val Ser
Val Leu Ser Val
Val Leu Val Ser
Val Ser Ile Val
Val Ser Leu Val
Val Ser Val Ile
Val Ser Val Leu
Val Thr Val Val
Val Val Ile Ser
Val Val Leu Ser
Val Val Ser Ile
Val Val Ser Leu
Val Val Thr Val
Val Val Val Thr
Forasartan
C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C66930 - Angiotensin II Receptor Antagonist
6-AMINO-5-(2,2-DIETHOXYETHYL)-2-((4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO)PYRIMIDIN-4(3H)-ONE
6-AMINO-5-(2,2-DIETHOXYETHYL)-2-((3-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO)PYRIMIDIN-4(3H)-ONE
1-BOC-4-[4-(4,4,5,5-TETRAMETHYL-[1,3,2]DIOXABOROLAN-2-YL)-BENZOYL]-PIPERAZINE
tert-butyl 4-[[2-(5-amino-3-methyl-1H-pyrazol-4-yl)-6-methoxy-phe noxy]methyl]piperidine-1-carboxylate
methyl 4-(10,13-dimethyl-3,7,12-trioxo-1,2,4,5,6,8,9,11,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl)pentanoate
1,3,8-Triazaspiro[4.5]dec-3-en-2-one, 4-(cyclohexylamino)-1-phenyl-8-(phenylmethyl)-
NCT-501
NCT-501 is a potent and selective theophylline-based inhibitor of aldehyde dehydrogenase 1A1 (ALDH1A1), inhibits hALDH1A1 with IC50 of 40 nM, typically shows better selectivity over other ALDH isozymes and other dehydrogenases (hALDH1B1, hALDH3A1, and hALDH2, IC50 >57 μM).
tert-Butyl 4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoyl)piperazine-1-carboxylate
Tonapofylline
C78273 - Agent Affecting Respiratory System > C29712 - Anti-asthmatic Agent > C319 - Bronchodilator Tonapofylline (BG 9928) is an orally active and selective adenosine A1 receptor antagonist with a Ki of 7.4 nM for human adenosine A1 receptor (hA1), which displays 915-fold selectivity versus human adenosine A2A receptor and 12-fold selectivity versus human adenosine A2B receptor and is used in development for the treatment of heart failure[1][2].
Pregnenolone succinate
C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C1636 - Therapeutic Steroid Hormone
Trecetilide
C78274 - Agent Affecting Cardiovascular System > C47793 - Antiarrhythmic Agent
3,17-Bis[(trimethylsilyl)oxy]estra-1,3,5(10)-triene
2-hydroxy-3-[6-hydroxy-5-[(E)-4-methyl-6-(2,6,6-trimethylcyclohexen-1-yl)hex-3-enyl]-3,6-dihydro-2H-pyran-2-yl]-2H-furan-5-one
(2-hydroxy-2-oxo-1,2lambda5-oxaphospholan-4-yl)methyl (E)-octadec-9-enoate
[3-carboxy-2-[(E)-13-carboxy-3-hydroxytridec-4-enoyl]oxypropyl]-trimethylazanium
[3-carboxy-2-[(E)-13-carboxy-3-hydroxytridec-9-enoyl]oxypropyl]-trimethylazanium
[3-carboxy-2-[(E)-13-carboxy-5-hydroxytridec-2-enoyl]oxypropyl]-trimethylazanium
[3-carboxy-2-[(E)-13-carboxy-3-hydroxytridec-5-enoyl]oxypropyl]-trimethylazanium
[3-carboxy-2-[(E)-13-carboxy-3-hydroxytridec-7-enoyl]oxypropyl]-trimethylazanium
vibsanin B
A vibsane diterpenoid that is (2Z,6E,10E)-cycloundeca-2,6,10-trien-1-one which is substituted at positions 2, 5, 5, 8, 9, and 9 by hydroxymethyl, methyl, 2-methylpent-2-en-5-yl, 3-methylbut-2-enoyloxy, hydroxy, and methyl groups, respectively (the 5S,8R,9R stereoisomer). It has been found to inhibit root growth in rice seedlings (IC50 0.14 mM).
Ala-Leu-Leu-Thr
A tetrapeptide composed of L-alanine, two L-leucine units, and L-threonine joined in sequence by peptide linkages.
5-Benzyl-2,3-bis(4-methoxyphenyl)-1,4-dimethylpiperazine
4-[[(3S,10R,13S,17S)-17-acetyl-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]-4-oxobutanoic acid
2-[4-(2,3-Dimethylphenyl)-1-piperazinyl]-1-(8-methyl-1,3,4,5-tetrahydropyrido[4,3-b]indol-2-yl)ethanone
16alpha,17beta-Dihydroxy-androst-4-en-3-one dipropionate
(3R)-3-[(2E,6E)-9-[(2S)-3,3-dimethyloxiran-2-yl]-3,7-dimethylnona-2,6-dienyl]-6-hydroxy-2,3,5-trimethyl-4-oxocyclohexa-1,5-diene-1-carboxylic acid
16alpha,17beta-Dihydroxyandrost-4-en-3-one dipropionate
(1e)-2-[(3s,4r,5s,7r)-7-hydroxy-5-methyl-5-(4-methylpent-3-en-1-yl)-3-(2-oxopropyl)-3,4,6,7-tetrahydro-1h-2-benzofuran-4-yl]ethenyl 3-methylbut-2-enoate
(3s,6s,12s)-12-benzyl-5,11-dihydroxy-1,6,7-trimethyl-3-(2-methylpropyl)-1,4,7,10-tetraazacyclododeca-4,10-diene-2,8-dione
(1e)-2-[(1s,5s,7r,8s,11r)-11-(2-hydroxypropan-2-yl)-8-methyl-5-(2-oxopropyl)-4-oxatricyclo[6.3.1.0²,⁶]dodec-2(6)-en-7-yl]ethenyl 3-methylbut-2-enoate
3-{5-[(2-hydroxy-5-methoxy-3-methylphenyl)methyl]-5,6,8a-trimethyl-2-oxo-hexahydro-1h-naphthalen-1-yl}propanoic acid
3-heptyl-7-methyl-6,8-dioxoisochromen-7-yl octanoate
10-hydroxy-9-[4-(5-hydroxy-3-methyl-2-oxocyclopent-3-en-1-yl)-3-methylbut-3-en-1-yl]-4,8,10-trimethyl-2-oxatricyclo[6.3.1.0⁴,¹²]dodecan-3-one
(1e)-2-[(1s,5s,7r,8s,11s)-11-(2-hydroxypropan-2-yl)-8-methyl-5-(2-oxopropyl)-4-oxatricyclo[6.3.1.0²,⁶]dodec-2(6)-en-7-yl]ethenyl 3-methylbut-2-enoate
4-{5-[2-(2,5,5,8a-tetramethyl-3,4,4a,6,7,8-hexahydronaphthalen-1-yl)ethyl]-6-hydroxy-3,6-dihydro-2h-pyran-2-yl}-5-hydroxy-5h-furan-2-one
(1r,2r,3z,5s,7e,11s)-8-formyl-5-[(2e)-4-hydroxy-4-methylpent-2-en-1-yl]-1,5-dimethyl-12-oxabicyclo[9.1.0]dodeca-3,7-dien-2-yl 3-methylbut-2-enoate
2-[1,5,5-trimethyl-9-oxo-10-(2-oxopropyl)-6-oxatricyclo[6.3.2.0⁴,¹³]tridecan-11-yl]ethenyl 3-methylbut-2-enoate
(1r,3r,4ar,5s,8ar)-5-[2-(furan-3-yl)ethyl]-1,4a,6-trimethyl-3-[(3-methylbutanoyl)oxy]-2,3,4,5,8,8a-hexahydronaphthalene-1-carboxylic acid
(1r,2s,4s,5s,7r,8s,9r)-3,3,7,9-tetramethyl-5-{[(2z)-2-methylbut-2-enoyl]oxy}-11-oxotricyclo[5.4.0.0²,⁸]undecan-4-yl (2z)-2-methylbut-2-enoate
(1as,3as,4r,5r,7r,7as,7br)-4,5,7a,7b-tetramethyl-4-[2-(5-oxo-2h-furan-3-yl)ethyl]-hexahydro-1ah-naphtho[1,2-b]oxiren-7-yl (2e)-2-methylbut-2-enoate
2-[11-(2-hydroxypropan-2-yl)-8-methyl-5-(2-oxopropyl)-4-oxatricyclo[6.3.1.0²,⁶]dodec-2(6)-en-7-yl]ethenyl 3-methylbut-2-enoate
1-[(1r,4s,5r,9s,10s,13r)-5-formyl-5,9-dimethyltetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadec-14-en-13-yl]methyl 4-methyl butanedioate
(1'r,2s,3r,4s,8'r,10'r,11'r,12's)-5'-methoxy-4,5,5,6',10',12'-hexamethyl-14'-oxaspiro[oxolane-2,13'-tetracyclo[9.3.2.0¹,¹⁰.0²,⁷]hexadecane]-2',4',6'-triene-3,8'-diol
(2e,5e)-2-[(3r)-3-hydroxy-3-[(2r)-2-hydroxy-5-oxo-2h-furan-3-yl]propylidene]-6-methyl-8-[(1s)-2,6,6-trimethylcyclohex-2-en-1-yl]oct-5-enal
(1r,2s,4r,6r,7r,8r)-3,3,7,9-tetramethyl-6-[(3-methylbutanoyl)oxy]-11-oxotricyclo[5.4.0.0²,⁸]undec-9-en-4-yl (2z)-2-methylbut-2-enoate
1-{1-[2-(furan-3-yl)ethyl]-1,4a,5-trimethyl-2,3,4,7,8,8a-hexahydronaphthalen-2-yl}methyl 4-methyl butanedioate
(2r,4r,5s,9s,13s,15s)-6-[(2s,3e,5r)-2,5-dihydroxyhex-3-en-2-yl]-4,15-dihydroxy-5-methyltetracyclo[11.4.1.0²,¹⁰.0⁵,⁹]octadeca-1(17),10-dien-12-one
(1r,4s,5r,9s,10s,13r,15s)-15-[(2s,3r)-2,3-dimethyloxirane-2-carbonyloxy]-5,9-dimethyl-14-methylidenetetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecane-5-carboxylic acid
(1z)-2-[(1r,2r,7s)-4-(hydroxymethyl)-2-methyl-2-(4-methylpent-3-en-1-yl)-5-oxo-7-(2-oxopropyl)cyclohept-3-en-1-yl]ethenyl 3-methylbut-2-enoate
(1e)-2-[11-(2-hydroxypropan-2-yl)-8-methyl-5-(2-oxopropyl)-4-oxatricyclo[6.3.1.0²,⁶]dodec-2(6)-en-7-yl]ethenyl 3-methylbut-2-enoate
(2r,3r)-2-[(3s,5r)-3,5-dimethyl-2-methylidene-6-{[(2r,3r)-3-(4-methylphenyl)oxiran-2-yl]methyl}hept-6-en-1-yl]-3-(4-methylphenyl)oxirane
(1ar,3ar,4r,5s,6s,7ar,7bs)-4,5,7a,7b-tetramethyl-4-[2-(5-oxo-2h-furan-3-yl)ethyl]-hexahydro-1ah-naphtho[1,2-b]oxiren-6-yl (2z)-2-methylbut-2-enoate
methyl (2s)-2-[(3r,6r)-6-[(2s,3as,4r,9bs)-3a,4,7,9b-tetramethyl-2h,3h,4h,5h-naphtho[1,2-b]furan-2-yl]-6-methyl-1,2-dioxan-3-yl]propanoate
(1as,3as,4r,5r,7r,7as,7br)-4,5,7a,7b-tetramethyl-4-[2-(5-oxo-2h-furan-3-yl)ethyl]-hexahydro-1ah-naphtho[1,2-b]oxiren-7-yl (2z)-2-methylbut-2-enoate
4,5,7a,7b-tetramethyl-4-[2-(5-oxo-2h-furan-3-yl)ethyl]-hexahydro-1ah-naphtho[1,2-b]oxiren-6-yl 2-methylbut-2-enoate
10β,13,14-trihydroxyalloaromadendrane
{"Ingredient_id": "HBIN000059","Ingredient_name": "10\u03b2,13,14-trihydroxyalloaromadendrane","Alias": "NA","Ingredient_formula": "C21H36O8","Ingredient_Smile": "CC1CCC2C1C3C(C3(C)CO)CCC2(COC4C(C(C(C(O4)CO)O)O)O)O","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "42560","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
5-epi-vibsanin c
{"Ingredient_id": "HBIN011533","Ingredient_name": "5-epi-vibsanin c","Alias": "NA","Ingredient_formula": "C25H36O5","Ingredient_Smile": "CC(=CCCC1(CC=C(C(=O)C(C1C=COC(=O)C=C(C)C)CC(=O)C)CO)C)C","Ingredient_weight": "416.5 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "7032","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "10319743","DrugBank_id": "NA"}
5-epi-vibsanin e
{"Ingredient_id": "HBIN011534","Ingredient_name": "5-epi-vibsanin e","Alias": "NA","Ingredient_formula": "C25H36O5","Ingredient_Smile": "CC(=CC(=O)OC=CC1C(C(=O)C2COC(C3C2CC1(CC3)C)(C)C)CC(=O)C)C","Ingredient_weight": "416.5 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "7033","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "44185775","DrugBank_id": "NA"}
alatoside a
{"Ingredient_id": "HBIN015044","Ingredient_name": "alatoside a","Alias": "NA","Ingredient_formula": "C21H36O8","Ingredient_Smile": "CC(=C)C1CCC2(C(C1)C(CC(C2OC3C(C(C(C(O3)CO)O)O)O)O)(C)O)C","Ingredient_weight": "416.5 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "838","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "11144190","DrugBank_id": "NA"}
atractyloside g
{"Ingredient_id": "HBIN017307","Ingredient_name": "atractyloside g","Alias": "NA","Ingredient_formula": "C21H36O8","Ingredient_Smile": "CC12CCC(CC1C(=C)C(C(C2)O)O)C(C)(C)OC3C(C(C(C(O3)CO)O)O)O","Ingredient_weight": "416.5 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "SMIT14423","TCMID_id": "1979","TCMSP_id": "NA","TCM_ID_id": "6487","PubChem_id": "101831405","DrugBank_id": "NA"}